Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Tactics used x Hedge Fund & MM to acquire shareholder stock
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5618)
•••
Comment by Noteableon Dec 08, 2022 10:43am
114 Views
Post# 35158969

RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stockAnother manipulative tactic used by hedge fund employess like SundayMovies aka Renee on the "Twits" message board has tried using, is to manipulatively criticize the CEO and management and then ask for their replacement as "Renee" has tried multiple times.

"She" was run off the "Twits" message board and now she and her "help" created identities here approximately 1 week ago.

____________________ 


 
Noteable - (12/7/2022 12:02:29 PM)
 
RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock
And yesterday's newly created alias Davidpark5 style of posting is like former Hcallahan44 who posts as Billyhenderson1988 on the 'twits" message board - and who is also "spitting fire and brimstone" sentiment over there in a manipulative attempt to distort and control the stock price.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities